The expanded use for Novo Nordisk's new basal insulin comes 15 months after the initial FDA approval.
Novo Nordisk has gained FDA approval for children and adolescents to use Tresiba (insulin degludec), the long-acting, once-a-day basal insulin that is the successor to Lantus.
Tresiba, approved by FDA in September 2015, is approved to improve glycemic control in patients with type 1 and type 2 diabetes from the age of 1 year through adulthood, making it the only insulin approved in both types of diabetes for patients that young.
A key advantage of Tresiba, its 25-hour half-life, would give young patients and their parents the flexibility of dosing just once a day.
“We are seeing a rise in the number of children and adolescents in the United States, especially those with type 2, and are proud to support these patients by offering new and effective treatment options,” said Todd Hobbs, MD, US chief medical officer for Novo Nordisk, in a statement. “It can be challenging for children with type 1 diabetes and their parents to manage blood sugar levels and keep up with multiple injections throughout an already busy day.”
FDA’s action was based on results of the BEGIN Young trial, a 26-week, phase 3b, randomized controlled trial which compared Tresiba’s results with those of Levemir (insulin determir, rDNA origin), a long-acting insulin analogue from Novo Nordisk approved in 2005. The results found that Tresiba improved glycemic control effectively in patients age 1 to 17 in combination with insulin aspart, a mealtime insulin.
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen
What We’re Reading: ACA Perception; FDA Blood Sugar Warning; AI and Physician Burnout
February 22nd 2024More than half of US adults have a favorable view of the Affordable Care Act (ACA); smartwatches and rings that claim to measure blood sugar levels without piercing the skin could be dangerous and should be avoided; many believe artificial intelligence (AI) could be the solution to physician burnout.
Read More
Advancements in Diabetes Technology: Coverage, Challenges, and Pregnancy Considerations
February 15th 2024Expert interviews highlight advancements and challenges in diabetes care technology, including automated insulin delivery systems and continuous glucose monitors, as well as improvements in insurance coverage.
Read More